Supplementary Figure S7. Total volume data for EGCG plus cetuximab in sensitive and resistant TNBC ortoxenograft. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
posted on 2023-03-31, 19:24authored byAriadna Giró-Perafita, Sònia Palomeras, David H. Lum, Adriana Blancafort, Gemma Viñas, Glòria Oliveras, Ferran Pérez-Bueno, Ariadna Sarrats, Alana L. Welm, Teresa Puig
(A) Mice bearing 231 and (B) 231DXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (0.5mg/mice 1 day a week) or the combination (EGCG plus cetuximab) for 12 days. (C) Mice bearing HCC and (D) HCCDXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (100uL/mice 1 day a week) or the combination (EGCG plus cetuximab) for 10 days. Total volume is shown as (Final Volume - Initial Volume). Dots are mean of each experimental group and bars, SEM. *(p < 0.05), **(p < 0.01) and ***(p < 0.001) indicate levels of statistically significance.